156 related articles for article (PubMed ID: 37399979)
21. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
22. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
[TBL] [Abstract][Full Text] [Related]
23. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
Heiblig M; Rea D; Chrétien ML; Charbonnier A; Rousselot P; Coiteux V; Escoffre-Barbe M; Dubruille V; Huguet F; Cayssials E; Hermet E; Guerci-Bresler A; Amé S; Sackmann-Sala L; Roy L; Sobh M; Morisset S; Etienne G; Nicolini FE
Exp Hematol; 2018 Nov; 67():41-48. PubMed ID: 30195076
[TBL] [Abstract][Full Text] [Related]
24. Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.
Frankfurt O; Licht JD
Clin Cancer Res; 2013 Nov; 19(21):5828-34. PubMed ID: 23935038
[TBL] [Abstract][Full Text] [Related]
25. The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data.
Luciano L; Annunziata M; Attolico I; Di Raimondo F; Maggi A; Malato A; Martino B; Palmieri F; Pane F; Sgherza N; Specchia G
Eur J Haematol; 2020 Jul; 105(1):3-15. PubMed ID: 32145037
[TBL] [Abstract][Full Text] [Related]
26. Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
Okabe S; Tauchi T; Kimura S; Maekawa T; Kitahara T; Tanaka Y; Ohyashiki K
PLoS One; 2014; 9(2):e89080. PubMed ID: 24586514
[TBL] [Abstract][Full Text] [Related]
27. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
Losson H; Gajulapalli SR; Lernoux M; Lee JY; Mazumder A; Gérard D; Seidel C; Hahn H; Christov C; Dicato M; Kirsch G; Han BW; Schnekenburger M; Diederich M
Pharmacol Res; 2020 Oct; 160():105058. PubMed ID: 32619722
[TBL] [Abstract][Full Text] [Related]
28. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
29. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
[TBL] [Abstract][Full Text] [Related]
30. Ponatinib-induced neutrophilic panniculitis.
Zhang M; Hassan KM; Musiek A; Rosman IS
J Cutan Pathol; 2014 Jul; 41(7):597-601. PubMed ID: 24602068
[TBL] [Abstract][Full Text] [Related]
31. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
[TBL] [Abstract][Full Text] [Related]
32. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
Kantarjian HM; Jabbour E; Deininger M; Abruzzese E; Apperley J; Cortes J; Chuah C; DeAngelo DJ; DiPersio J; Hochhaus A; Lipton J; Nicolini FE; Pinilla-Ibarz J; Rea D; Rosti G; Rousselot P; Shah NP; Talpaz M; Srivastava S; Ren X; Mauro M
Am J Hematol; 2022 Nov; 97(11):1419-1426. PubMed ID: 36054756
[TBL] [Abstract][Full Text] [Related]
33. Perturbation of p38α MAPK as a Novel Strategy to Effectively Sensitize Chronic Myeloid Leukemia Cells to Therapeutic BCR-ABL Inhibitors.
Kuo YH; Wei SH; Jiang JH; Chang YS; Liu MY; Fu SL; Huang CF; Lin WJ
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830455
[TBL] [Abstract][Full Text] [Related]
34. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.
Katagiri S; Tauchi T; Okabe S; Minami Y; Kimura S; Maekawa T; Naoe T; Ohyashiki K
Clin Cancer Res; 2013 Mar; 19(6):1422-32. PubMed ID: 23319824
[TBL] [Abstract][Full Text] [Related]
35. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2018 Mar; 93(3):442-459. PubMed ID: 29411417
[TBL] [Abstract][Full Text] [Related]
36. Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options.
Meenakshi Sundaram DN; Jiang X; Brandwein JM; Valencia-Serna J; Remant KC; Uludağ H
Drug Discov Today; 2019 Jul; 24(7):1355-1369. PubMed ID: 31102734
[TBL] [Abstract][Full Text] [Related]
37. Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia.
Cortes J; Radich J; Mauro MJ
Clin Adv Hematol Oncol; 2012 Oct; 10(10 Suppl 19):1-16. PubMed ID: 23187745
[TBL] [Abstract][Full Text] [Related]
38. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.
Mian AA; Rafiei A; Haberbosch I; Zeifman A; Titov I; Stroylov V; Metodieva A; Stroganov O; Novikov F; Brill B; Chilov G; Hoelzer D; Ottmann OG; Ruthardt M
Leukemia; 2015 May; 29(5):1104-14. PubMed ID: 25394714
[TBL] [Abstract][Full Text] [Related]
39. Ponatinib: A Third-Generation Inhibitor for the Treatment of CML.
Wehrle J; von Bubnoff N
Recent Results Cancer Res; 2018; 212():109-118. PubMed ID: 30069627
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]